Evidence map›Paper›PMID 29358969›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2017

A New Chinese Medicine Intestine Formula Greatly Improves the Effect of Aminosalicylate on Ulcerative Colitis.

Baohai Liu, Xuehua Piao, Lianyi Guo, Guijun Wang, Weihua Sun, Leming Gao, Xuefeng Zheng, Yanli Fang

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Baohai LiuDepartment of Gastroenterology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Xuehua PiaoDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.ORCID 0000-0003-3310-4183
Lianyi GuoDepartment of Gastroenterology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Guijun WangDepartment of Gastroenterology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Weihua SunDepartment of Gastroenterology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Leming GaoAdministrative Logistics, The 2nd Dental Center, Peking University School of Stomatology, Beijing 100101, China.
Xuefeng ZhengDepartment of Gastroenterology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Yanli FangDepartment of Gastroenterology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121001, China.
Jinzhou Medical University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ulcerative colitis (UC) is a chronic lifelong inflammatory disorder of the colon. Current medical treatment of UC relies predominantly on the use of traditional drugs, including aminosalicylates, corticosteroids, and immunosuppressants, which failed to effectively control this disease's progression and produced various side effects. Here, we report a new Chinese medicine intestine formula (CIF) which greatly improved the effect of mesalazine, an aminosalicylate, on UC. In the present study, 60 patients with chronic UC were treated with oral mesalazine alone or in combination with CIF enema. The combination of mesalazine and CIF greatly and significantly improved the clinical symptoms and colon mucosal condition and improved the Mayo Clinic Disease Activity Index and health-related quality of life, when compared to mesalazine alone. In particular, the addition of CIF further decreased serum levels of tumor necrosis factor-alpha and hypersensitivity C-reactive protein but in contrast increased interleukin-4. Thus, the results demonstrate the beneficial role of CIF in UC treatment, which may be mediated by the regulation of inflammation.

Identifiers

PMID29358969
PMCPMC5735632
OpenAlexW2770366264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.